Current and emerging therapies in unresectable and recurrent gastric cancer

Erin Jou, Lakshmi Rajdev

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

Gastric cancer is one of the most lethal cancers worldwide despite many advances and options in therapy. As it is often diagnosed at an advanced stage, prognosis is poor with a median overall survival of less than twelve months. Chemotherapy remains the mainstay of treatment for these patients but it confers only a moderate survival advantage. There remains a need for new targeted treatment options and a way to better define patient populations who will benefit from these agents. In the past few years, there has been a better understanding of the biology, molecular profiling, and heterogeneity of gastric cancer. Our increased knowledge has led to the identification of gastric cancer subtypes and to the development of new targeted therapeutic agents. There are now two new targeted agents, trastuzumab and ramucirumab, that have recently been approved for the treatment of advanced and metastatic gastric cancer. There are also many other actively investigated targets, including epidermal growth factor receptor, the phosphatadylinositol 3-kinase/protein kinase B/mammalian target of rapamycin pathway, c-Met, poly ADP-ribose polymerase, and immune checkpoint inhibition. In this review, we discuss the current management of advanced gastric cancer as well as emerging targeted therapies and immunotherapy.

Original languageEnglish (US)
Pages (from-to)4812-4823
Number of pages12
JournalWorld Journal of Gastroenterology
Volume22
Issue number20
DOIs
StatePublished - May 28 2016

    Fingerprint

Keywords

  • Advanced gastric cancer
  • Human epidermal growth factor receptor type 2
  • Immunotherapy
  • Targeted therapy
  • Vascular endothelial growth factor receptor

ASJC Scopus subject areas

  • Gastroenterology

Cite this